Clostridium difficile infection and proton pump inhibitors

Area of Science:

• Gastroenterology
• Infectious Diseases
• Pharmacology

Background:

• Clostridium difficile is a significant cause of infectious diarrhea, particularly in healthcare settings.
• Antibiotic use is a primary risk factor for developing C. difficile infection.
• Patients with chronic medical conditions are more susceptible to C. difficile-associated diarrhea.

Purpose of the Study:

• To review the established association between proton pump inhibitor (PPI) use and C. difficile-associated diarrhea (CDAD).
• To explore the implications of this association in various patient populations and settings.

Main Methods:

• Literature review of studies investigating the link between PPIs and CDAD.
• Analysis of epidemiological data and clinical reports.

Main Results:

• Proton pump inhibitors are frequently associated with an increased risk of C. difficile-associated diarrhea.
• This association is observed in both outpatient and inpatient environments.
• CDAD linked to PPI use has also been documented in pediatric populations.

Conclusions:

• A clear association exists between proton pump inhibitor therapy and Clostridium difficile infection.
• Preventative strategies include judicious prescribing of PPIs and antibiotics, alongside infection control measures like hand hygiene and patient isolation.